Syneron Medical Ltd. (NASDAQ:ELOS)

This former Rule Breaker has bounced back pretty well from our sell recommendation in 2009. It has a lot of cash (always did), so the underlying business isn't priced for much. I'll rejoin the fray on this one and give it another green thumb. Please note, this may be a contrary indicator: I struck out in my first at-bat with ELOS.

Following Seth Klarman's lead.

24% cheaper than Klarman's buy.

Just hit the 100 mva on the daily 1 year chart. May close the gap at the 11.70 area. Expect buyers around this. Undervalued, with some brokers targeting $17.25

Good earnings.

stock of the day

It's profits are shrinking that's just not a good sign long term.

Stock is trading just above cash but there is significant macro pressure on elective surgery, plus competition from Cutera, Cynosure and Candela. There's a reason all 4 stocks are trading at enterprise value, because all 4 aren't going to make it through this recession.

bravobevo

Great growth and future earnings.

Medical technology good long-term value.

Sells at cash value. Are you kidding?

Deep value play for a number of prominent investors has become an even deeper value after recent earnings miss. Sub $10 looks like good entry point - technicals suggest we are nearing short-term bottom, while value metrics seem compelling - debt free, 60% of market cap in cash, small premium to book. Likely dead money for a while, but solid 3-5 year recovery prospects from current level.

The company might have a stagnant price in the short term, but should outperform over a longer time frame. They've been consistently profitable in an industry where most products fizzle out. Their margins have been declining, but it's mainly the result of increased R&D. Their main product still retains VERY healthy margins. Also, the company has about $50 million in cash and equivalents and around $130 in marketable securities. So taking those measures out, the actual on-going business value of the company is only trading at about 6 X earnings.

Aesthetic medical products like Syneron's offerings are benefiting from demographic shifts and increasing personal wealth for women. It's a good market to be in. Also, the company currently has about 50% of its sales in North America, so I think there are several other regions where it could experience high growth in coming years.

Still a way to go...down. Not a buy...yet.

Technical bottom, Fantastic balance sheet, net income to sales ratio is high (20 to 50%), no capital needed to grow, tiny depreciation charge, some great and famous individual investors are accumulating it. What I call a growth company at a value price.

People might not be too excited about spending more money on their products, while the credit card debt, mortgage, prices in general are all increasing. Also, more people are losing their jobs. Might be best to stay away from these stocks for now.

This company has solid fundamentals. Low Price to book ratio. Low debt to equity and solid earnings. In this bear market you need whatever good companies you can find.

You gotta love a BEAR market. There are so many great stocks trading at levels I usually only dream about. Not much of a downside here. Expect a minimum of a 50% return, but closer to 75-100%. Dont b fooled fools, this is know value trap. 0 debt and mgmt buying back shares.